Find and Pitch Jounalists, Get Your Story Covered

Tags: carboplatin atezolizumab breast cancer obesity paclitaxel

	Profile	Recent Articles on Subject
1	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Is New Standard of Care for High-Risk Early-Stage TNBC - 4 days ago Phase 3 Study Supports Pembrolizumab Plus Lenvatinib as Standard of Care in Patients With Advanced Endometrial Cancer Who Received Prior Platinum Therapy - 11 months ago
2	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer - 5 days ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 8 days ago Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma - 15 days ago Novel PARP1 Inhibitor Shows Promise in Breast Cancer - 5 months ago Chemotherapy/ICI Combos Falter as Second-Line Treatment for Gastric Cancer - 6 months ago Rucaparib Maintenance Boosts PFS in Metastatic, Recurrent Endometrial Cancer - 6 months ago First-Line Nivolumab Plus Chemo Approved for Bladder Cancer - 7 months ago Novel Therapy Promising for Radiation-Induced Oral Mucositis - 7 months ago Two Pembrolizumab Trials in Head and Neck Cancer Yield Divergent Results - 7 months ago New First-Line Option for Pancreatic Cancer Approved - 7 months ago Cabozantinib Plus Atezolizumab Delays Progression in mCRPC - 8 months ago Olaparib-Abiraterone in Biomarker-Selected mCRPC Tops Each Agent Alone - 8 months ago Atezolizumab Plus Carboplatin Boosts Survival in Metastatic TNBC - 9 months ago FDA OKs First Drug for Nasopharyngeal Carcinoma - 11 months ago Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers - 11 months ago Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer - 11 months ago Pembrolizumab Wins FDA Approval in Operable Lung Cancer - 11 months ago
3	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Grants Orphan Drug Designation to PT217 for Neuroendocrine Carcinoma - about 1 month ago Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer - 6 months ago Pembrolizumab, Chemoradiotherapy Meet Overall Survival Endpoint for Cervical Cancer - 6 months ago FDA Approves Rybrevant as First-Line Treatment for NSCLC - 7 months ago Biosimilar SB8 Is Comparable to Bevacizumab for Non–Small Cell Lung Cancer - 7 months ago Celltrion Seeks Approval From FDA for CT-P47 as Biosimilar of Tocilizumab - 8 months ago FDA Approves Enfortumab Vedotin, Pembrolizumab for Treatment of Urothelial Cancer - 9 months ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - 10 months ago Datopotamab Deruxtecan Demonstrates Improvement in Progression-Free Survival in HR+, HER2- Breast Cancer - 12 months ago
4	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder - 2 months ago
5	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Durvalumab Plus Chemotherapy to Treat Endometrial Cancer - 3 months ago Phase 3 Trial of Pembrolizumab with Olaparib Did Not Meet Endpoints Among Individuals with NSCLC - 6 months ago Novel Chemotherapy Method Could Decrease Lung Cancer Tumor Size - 7 months ago FDA Approves Irinotecan Liposome for Metastatic Pancreatic Adenocarcinoma - 7 months ago FDA Approves Pembrolizumab Plus Chemotherapy to Treat Metastatic HER2-Negative Gastric, Gastroesophageal Junction Adenocarcinoma - 10 months ago
6	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study - 3 months ago Non-Covalent BTK Inhibitor Approved for CLL - 10 months ago New Oral Drug Approved for Metastatic Colorectal Cancer - 11 months ago
7	Ryan Haumschild, PharmD, MS, MBA Pharmacy Times Director of Pharmacy. Editorial Board member. Atlanta, Georgia pharmacyhealthcareeditorial workadvisory	Alternative Treatments for eBC and mBC - 3 months ago
8	Mike Hennessy Jr, President and CEO Pharmacy Times Pro middleweight boxer. UK/Ireland. BoxingSports	Navigating Oncology Drug Shortages: Ethical Frameworks and Strategic Management - 3 months ago
9	Danielle Gerhard, PhD The Scientist Assistant Editor @TheScientistLLC. United Kingdom scienceediting	Infographic: Understanding CAR-T vs TCR Approaches - 6 months ago Bugs as Drugs to Boost Cancer Therapy - 8 months ago
10	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	CART T-Cell Therapy A2B530 Receives Orphan Drug Designation for the Treatment of Colorectal Cancer - 7 months ago FDA Accepts BLA for Datopotamab Deruxtecan for the Treatment of NSCLC - 7 months ago

Journalists covering carboplatin